Navigation Links
New Analyses Presented at ASCO Reaffirmed Efficacy and Safety of TORISEL in Patients With Advanced Kidney Cancer

- Data Showed Overall Survival Benefit With TORISEL Regardless of Nephrectomy Status; Additional Analysis Examined Specific Side Effects -

COLLEGEVILLE, Pa., May 31 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced results of two new analyses of the pivotal study of the mTOR (mammalian target of rapamycin) inhibitor TORISEL(R) (temsirolimus), the only renal cancer therapy proven to extend median overall survival compared with interferon-alpha in patients with advanced renal cell carcinoma (RCC). These analyses, which are being presented at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, reaffirm the efficacy and safety of TORISEL for the treatment of advanced RCC. TORISEL is the only approved cancer therapy that specifically inhibits the mTOR kinase, an important regulator of cell proliferation, cell growth and cell survival.

RCC will account for approximately 85 percent of renal cancers. There are an estimated 54,390 new cases of kidney and renal pelvis cancer diagnosed in the United States each year, and about 40 percent of patients have advanced disease at the time of diagnosis.

TORISEL was studied in a three-arm, phase 3 clinical trial of 626 patients with advanced RCC with three or more of six preselected prognostic risk factors who had received no prior systemic therapy. Results of this study demonstrated that TORISEL significantly increased median overall survival by 49 percent compared with interferon-alpha (10.9 months [95% CI: 8.6, 12.7] vs. 7.3 months [6.1, 8.8], P=0.0078) (Hazard Ratio [95% CI] = 0.73 [0.58, 0.92]).

"In summary, these analyses provide clinicians with additional information about the efficacy and safety of TORISEL for the treatment of advanced RCC patients. Wyeth is committed to the continued exploration of mTOR inhibition with TORISEL for the treatment of a variety of cancers," says Joseph S. Camardo, M.D., Senior Vice President, Global Medical Affairs, Wyeth Pharmaceuticals.

Abstract 5050: Exploratory Analysis of the Influence of Nephrectomy Status on Temsirolimus Efficacy in Patients With Advanced Renal Cell Carcinoma and Poor-Risk Features

This retrospective subgroup analysis evaluated whether the nephrectomy status (whether or not patients had undergone surgery for removal of the affected kidney) of patients with advanced RCC enrolled in the pivotal phase 3 study had an effect on the observed overall survival benefit of TORISEL compared with interferon-alpha. Investigators determined that both overall survival and progression-free survival were longer for patients treated with TORISEL compared with those treated with interferon-alpha, regardless of whether they had undergone nephrectomy. In addition, among patients who had not undergone nephrectomy, more patients treated with TORISEL showed reductions in the size of their primary kidney tumor than those treated with interferon-alpha (58% vs. 31%).

Abstract 5116: Characterization of Hyperglycemia, Hypercholesterolemia and Hyperlipidemia in Patients With Advanced Renal Cell Carcinoma Treated With Temsirolimus or Interferon-Alpha

Another analysis presented at the ASCO meeting examined specific side effects seen in the pivotal phase 3 study of TORISEL for advanced RCC, including high levels of blood glucose (hyperglycemia), cholesterol (hypercholesterolemia), and lipids (hyperlipidemia). More patients treated with TORISEL, either with or without diabetes, developed hyperglycemia of grade 2 or higher (P=0.002 for diabetic patients, P=0.001 for non-diabetic patients), compared with those treated with interferon-alpha. TORISEL also was associated with the development of hypercholesterolemia of grade 2 or higher, compared with interferon-alpha (P=0.001), but there was not a significant increase in hyperlipidemia versus interferon-alpha (P=0.675). However, the development of hyperglycemia or hypercholesterolemia did not have affect on overall survival or progression-free survival in this study.

The clinical data for TORISEL presented at the meeting represent only a portion of the totality of the safety and efficacy data from the ongoing clinical development of TORISEL.


TORISEL is an mTOR inhibitor. Inhibition of mTOR in treated cancer cells blocked the translation of genes that regulate the cell cycle. In in vitro studies using renal cancer cell lines, TORISEL inhibited the activity of mTOR and resulted in reduced levels of certain cell growth factors involved in the development of new blood vessels, such as vascular endothelial growth factor.

TORISEL is approved for the treatment of advanced RCC in the United States, European Union and other markets, based on results of a phase 3 clinical study that demonstrated that TORISEL improves overall survival for patients with advanced RCC compared with interferon-alpha.

Important Safety Information

Hypersensitivity reactions manifested by symptoms, including, but not limited to anaphylaxis, dyspnea, flushing and chest pain have been observed with TORISEL.

Serum glucose, serum cholesterol and triglycerides should be tested before and during treatment with TORISEL.

The use of TORISEL is likely to result in hyperglycemia and hyperlipemia. This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy and/or lipid-lowering agents, respectively.

The use of TORISEL may result in immunosuppression. Patients should be carefully observed for the occurrence of infections, including opportunistic infections.

Cases of interstitial lung disease, some resulting in death, have occurred. Some patients were asymptomatic and others presented with symptoms. Some patients required discontinuation of TORISEL and/or treatment with corticosteroids and/or antibiotics.

Cases of fatal bowel perforation occurred with TORISEL. These patients presented with fever, abdominal pain, metabolic acidosis, bloody stools, diarrhea and/or acute abdomen.

Cases of rapidly progressive and sometimes fatal acute renal failure not clearly related to disease progression occurred in patients who received TORISEL.

Due to abnormal wound healing, use TORISEL with caution in the perioperative period.

Patients with central nervous system tumors (primary CNS tumor or metastases) and/or receiving anticoagulation therapy may be at an increased risk of developing intracerebral bleeding (including fatal outcomes) while receiving TORISEL.

Live vaccinations and close contact with those who received live vaccines should be avoided.

Patients and their partners should be advised to avoid pregnancy throughout treatment and for 3 months after TORISEL therapy has stopped.

The most common (incidence greater than or equal to 30%) adverse reactions observed with TORISEL are: rash (47%), asthenia (51%), mucositis (41%), nausea (37%), edema (35%), and anorexia (32%). The most common laboratory abnormalities (incidence greater than or equal to 30%) are anemia (94%), hyperglycemia (89%), hyperlipemia (87%), hypertriglyceridemia (83%), elevated alkaline phosphatase (68%), elevated serum creatinine (57%), lymphopenia (53%), hypophosphatemia (49%), thrombocytopenia (40%), elevated AST (38%), and leukopenia (32%).

Most common Grades 3/4 adverse events included asthenia (11%), dyspnea (9%), hemoglobin decreased (20%), lymphocytes decreased (16%), glucose increased (16%), phosphorus decreased (18%) and triglycerides increased (44%).

Strong inducers of CYP3A4/5 (e.g., dexamethasone, rifampin) and strong inhibitors of CYP3A4 (e.g., ketoconazole, atazanavir) may decrease and increase concentrations of the major metabolite of TORISEL, respectively. If alternatives cannot be used, dose modifications of TORISEL are recommended.

St. John's Wort may decrease TORISEL plasma concentrations, and grapefruit juice may increase plasma concentrations of the major metabolite of TORISEL, and therefore both should be avoided.

The combination of TORISEL and sunitinib resulted in dose-limiting toxicity (Grade 3/4 erythematous maculopapular rash, and gout/cellulitis requiring hospitalization).

Please see TORISEL full Prescribing Information at

Wyeth Pharmaceuticals

Wyeth Pharmaceuticals, a division of Wyeth, has leading products in the areas of women's health care, infectious disease, gastrointestinal health, central nervous system, inflammation, transplantation, hemophilia, oncology, vaccines and nutritional products.

Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products, nutritionals and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.

The statements in this press release that are not historical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, the inherent uncertainty of the timing and success of, and expense associated with, research, development, regulatory approval and commercialization of our products and pipeline products; government cost- containment initiatives; restrictions on third-party payments for our products; substantial competition in our industry, including from branded and generic products; emerging data on our products and pipeline products; the importance of strong performance from our principal products and our anticipated new product introductions; the highly regulated nature of our business; product liability, intellectual property and other litigation risks and environmental liabilities; uncertainty regarding our intellectual property rights and those of others; difficulties associated with, and regulatory compliance with respect to, manufacturing of our products; risks associated with our strategic relationships; economic conditions including interest and currency exchange rate fluctuations; changes in generally accepted accounting principles; trade buying patterns; the impact of legislation and regulatory compliance; risks and uncertainties associated with global operations and sales; and other risks and uncertainties, including those detailed from time to time in our periodic reports filed with the Securities and Exchange Commission, including our current reports on Form 8-K, quarterly reports on Form 10-Q and annual report on Form 10-K, particularly the discussion under the caption "Item 1A, Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2007, which was filed with the Securities and Exchange Commission on February 29, 2008. The forward-looking statements in this press release are qualified by these risk factors. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

SOURCE Wyeth Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. New MIRCERA(R) Data Analyses to be Featured at the American Society of Nephrology Annual Meeting
2. New Analyses of Long-Term LIALDA(TM) (mesalamine) Data Presented at ACG
3. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
4. Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
5. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
6. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
7. Data To Be Presented at ASCO Supports Potential of Peregrines Cotara(R) for the Treatment of Brain Cancer
8. About 60 Clinical Studies Regarding Schering-Ploughs Oncology Compounds Will be Presented at ASCO
9. Two DOXIL(R) Studies to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting
10. Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration
11. Safety and Efficacy Results Presented From Largest Prospective Controlled Clinical Study of Ulcerative Colitis
Post Your Comments:
(Date:10/9/2015)... , October 9, 2015 ... major players. --> India ... --> announces addition of 3 divalproex ... 2020 forecasts for global markets as well as ... along with analysis of major players. ...
(Date:10/9/2015)... 9, 2015  The Centers for Disease Control ... and Zoonotic Infectious Diseases, Office of Advanced Molecular ... a research collaboration to evaluate the performance of ... this research collaboration is to evaluate the utility ... health and infectious disease applications. This collaboration will ...
(Date:10/9/2015)... ClinicalKey Nursing debuts at ...   Elsevier , a world-leading provider of ... ClinicalKey for Nursing , a new clinical reference platform ... unique needs of nursing professionals. Attendees of the ANCC ... Oct. 7-9, will have the opportunity to demo ClinicalKey Nursing ...
Breaking Medicine Technology:
... plan for various study outcomes, MEXICO CITY, Aug. ... a new report, Anticipating the Results of PrEP,Trials, calling ... and advocates to prepare for initial,results - expected as ... drugs being tested for HIV prevention, known as PrEP ...
... is pleased,to announce the dosing of the first patient ... of AEG35156, a second generation antisense,therapeutic targeting XIAP, a ... The study, made possible, in part, by funding from ... Multicenter, Open-Label Study,of the X- Linked Inhibitor of Apoptosis ...
Cached Medicine Technology:
(Date:10/9/2015)... ... October 09, 2015 , ... ... welcoming individuals from all walks of life to save money on the high ... of $25 per month per medication, individuals and families can receive their medications ...
(Date:10/9/2015)... ... October 09, 2015 , ... ViewPoint Center, a teen mental health hospital ... mental illness, the stigma associated with mental illness causes many to hide away in ... importance of supporting teens with mental illness , providing teens with comprehensive diagnostic ...
(Date:10/9/2015)... Colorado (PRWEB) , ... October 09, 2015 , ... ... Station, one of the oldest and largest recreational dispensaries in Colorado, says the ... cannabis business is growing rapidly and maturing into a legitimate industry. , ...
(Date:10/9/2015)... (PRWEB) , ... October 09, 2015 , ... ... assisted living placement counseling, recently opened its newest office in Maryland – its ... care industry with a background as a project management technology consultant to many ...
(Date:10/9/2015)... ... ... Smanos was featured on NewsWatch as part of its monthly Tech Report, which features ... and special reporter for NewsWatch, conducted the review and shared with viewers how this ... age it’s more important than ever to keep homes and dorms safe and protected. ...
Breaking Medicine News(10 mins):
... of infamous psychological obedience study in 1960s , , MONDAY, ... as willing to follow orders to hurt others as they ... , In a replication of one of the most famous ... give what they believed were increasingly painful electric shocks to ...
... , WHAT: YEAR-IN-PREVIEW WEBINAR ... Wednesday, January 7, 2009 11:00 AM (U.S. Eastern Time) ... ENROLL: Please use the link below to register ... Millennium Research Group (MRG) complimentary webinar identifying the top 10 ...
... will be the subject of a policy forum sponsored ... January 13, 2009, from 3:00 p.m. until 4:30 p.m. ... Suites Resort, 5001 N. Scottsdale Road, Scottsdale, Arizona. This ... explore the relationship between health insurance coverage and access ...
... Mo., Jan. 5 The recent tragic death of Jett ... which he was diagnosed in early childhood. Kawasaki disease is ... the age of five. The disease occurs more often in ... and Korean descent. Although most children diagnosed with Kawasaki recover ...
... AUGUSTA, Ga. Just days after the first retinal ... start committing suicide and researchers believe their death may ... infection. , Understanding the cell death may also provide ... retina responds to assault, whether by infection or a ...
... WASHINGTON, Jan. 5 Despite a deepening recession, only ... raise less money this year than in 2008 said ... services for the poor and underinsured, according to a ... Philanthropy ( ).The overwhelming majority of AHP members ...
Cached Medicine News:
Incontinence Pessaries...
Incontinence Dish - Stress Incontinence with mild prolapse. Incontinence Dish with support - Stress Incontinence with mild prolapse and mild cystocele...
The Set comes with a cross reference chart that translates ring size into the correct size of other EvaCare pessaries. The Fitting Set can be disinfected in three ways: autoclaved, boiled or cold ste...
The donut pessary is designed for third degree prolapse as well as cystocele and rectocele. The soft donut can be compressed for insertion. It is available in seven sizes....
Medicine Products: